Global Cancer News


Want up-to-date Cancer News? Here’s your online resource for Global Cancer News and Information. We offer resources on various issues for people diagnosed with cancer and family members with cancer.

Green tea component upsets cancer cell metabolism

A new study reported in the journal Metabolomics, explores the effect of “epigallocatechin gallate” or “EGCG,” an active biological agent of green tea which changes the metabolism of pancreatic cancer cells by suppressing the expression of lactate dehydrogenase A or LDHA, a critical enzyme in cancer metabolism and slows down its progression.

The latest study, from Dr. Wai-Nang Lee of the Los Angeles Biomedical Research Institute (LA BioMed) and colleagues found EGCG disrupts metabolic flux in cancer cells in a similar way to oxamate, a known inhibitor of LDHA. They concluded that both EGCG and oxamate reduced the risk of cancer by suppressing the activity of LDHA, which in turn disrupts metabolic functions in cancer cells.

“By explaining how green tea’s active component could prevent cancer, this study will open the door to a whole new area of cancer research and help us understand how other foods can prevent cancer or slow the growth of cancerous cells.” Dr. Lee commented.

News sourced from

Drug found to prolong life after prostate cancer

Christopher Sweeney of Dana-Farber Cancer Institute in Boston, led the study on prostate cancer and shared the results yesterday at the American Society of Clinical Oncology’s annual conference in Chicago. Doctors reported decades-old chemotherapy drug extended life by more than a year when added to standard hormone therapy for men whose prostate cancer has widely spread.

All 790 men in the study received drugs to block testosterone, which fuels prostate cancer’s growth, and half also were given six infusions of docetaxel, one every three weeks. The study found that men who received docetaxel, sold as Taxotere and in generic form, lived nearly 58 months, vs. 44 months for those not given the drug.

About 2 1/2 years later, 101 of the men given docetaxel had died vs. 136 of the men who did not get it. One man died from the treatment and about 6 percent had fevers from low blood counts, but most were able to tolerate treatment well, Sweeney said.

Cancer news sourced from

£13 Million Investment in Cancer Drug Discovery

An important milestone has been reached in the clinical development of ALM201, an innovative new cancer drug. Almac and Queen’s University Belfast’s CCRCB (Centre for Cancer Research and Cell Biology) have formed a £13million partnership for accelerated cancer-oriented drug discovery. Queen’s and Almac are recognised internationally as being leading innovators in the world of drug discovery and cancer research. Today’s announcement, therefore, heralds an important new era for patients. The newest collaboration will also result in an increase in the development of potential new therapeutic approaches for patients, and accelerate the process in which treatments move from the lab bench to bedside.

Almac is a highly respected and successful drug development company focusing on innovative cancer treatments that have global potential. This significant investment in Research and Development will enhance collaboration between academia and industry, ensuring that the investment is maximized, that research is effectively commercialized and that ultimately, enhanced treatment solutions are made available to cancer patients.

Cancer news sourced from